Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Dr |
m WP:CHECKWIKI error 18 fixes + general fixes (BRFA 15) using AWB (7832) |
||
| Line 26: | Line 26: | ||
'''CB-13''' ('''SAB-378''')<ref>{{Cite doi|10.1124/jpet.110.169946}}</ref> is a [[cannabinoid]] drug, which acts as a potent [[agonist]] at both the [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and [[Cannabinoid receptor type 2|CB<sub>2</sub>]] receptors, but has poor [[blood-brain barrier]] penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as [[catalepsy]] only appearing at much higher dose ranges. It has [[hyperalgesia|antihyperalgesic]] properties in animal studies,<ref>Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O'Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. ''Journal of Medicinal Chemistry''. 2007 Aug 9;50(16):3851-6. PMID 17630726</ref> and has progressed to preliminary human trials.<ref name="pmid19144772">{{cite journal |author=Gardin A, Kucher K, Kiese B, Appel-Dingemanse S |title=Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety |journal=Drug Metabolism and Disposition: the Biological Fate of Chemicals |volume=37 |issue=4 |pages=827–33 |year=2009 |month=April |pmid=19144772 |doi=10.1124/dmd.108.024000 |url= |issn=}}</ref> |
'''CB-13''' ('''SAB-378''')<ref>{{Cite doi|10.1124/jpet.110.169946}}</ref> is a [[cannabinoid]] drug, which acts as a potent [[agonist]] at both the [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and [[Cannabinoid receptor type 2|CB<sub>2</sub>]] receptors, but has poor [[blood-brain barrier]] penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as [[catalepsy]] only appearing at much higher dose ranges. It has [[hyperalgesia|antihyperalgesic]] properties in animal studies,<ref>Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O'Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. ''Journal of Medicinal Chemistry''. 2007 Aug 9;50(16):3851-6. PMID 17630726</ref> and has progressed to preliminary human trials.<ref name="pmid19144772">{{cite journal |author=Gardin A, Kucher K, Kiese B, Appel-Dingemanse S |title=Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety |journal=Drug Metabolism and Disposition: the Biological Fate of Chemicals |volume=37 |issue=4 |pages=827–33 |year=2009 |month=April |pmid=19144772 |doi=10.1124/dmd.108.024000 |url= |issn=}}</ref> |
||
==References== |
==References== |
||
| Line 32: | Line 31: | ||
{{Cannabinoids}} |
{{Cannabinoids}} |
||
| ⚫ | |||
[[Category:Cannabinoids]] |
[[Category:Cannabinoids]] |
||
[[Category:Naphthalenes]] |
[[Category:Naphthalenes]] |
||
[[ |
[[Category:Aromatic ketones]] |
||
[[ |
[[Category:Naphthol ethers]] |
||
| ⚫ | |||
Revision as of 14:26, 10 September 2011
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H24O2 |
| Molar mass | 368.467 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
CB-13 (SAB-378)[1] is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood-brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,[2] and has progressed to preliminary human trials.[3]
References
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1124/jpet.110.169946, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1124/jpet.110.169946instead. - ^ Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O'Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. Journal of Medicinal Chemistry. 2007 Aug 9;50(16):3851-6. PMID 17630726
- ^ Gardin A, Kucher K, Kiese B, Appel-Dingemanse S (2009). "Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37 (4): 827–33. doi:10.1124/dmd.108.024000. PMID 19144772.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)